10X Genomics Inc (TXG) support and resistance · rev $610.8M
10X Genomics Inc (TXG) is a health information services company listed on NASDAQ.
This page maps 10X Genomics Inc (TXG) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported TXG revenue for 2024-12-31 was $610.8M. Net income was -$182.6M. Revenue was down 1.3% from 2023-12-31 to 2024-12-31. TXG currently screens at market cap $4.08B.
TXG currently screens at market cap $4.08B. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new TXG 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the TXG quote page for the session range and the stock page for the full model.
Not investment advice.